Biodesix Q1 revenue $25.6M (+42% YoY); raises FY 2026 revenue guidance to $108-114M

BIODESIX INC

2026-Q1 EPS reported -$0.81 revenue$25,555,000

Total revenue $25.6M, +42% YoY; Diagnostic Testing $22.3M (+37%), Development Services $3.3M (+99%).
Test volumes up 29% to 17,800; average revenue per test improved on expanded payer coverage and RCM enhancements.
Gross margin 82% (excl. one-time $0.4M recovery), up 300 bps YoY; net loss $7.8M (improved 30%); Adj. EBITDA loss $4.1M (improved 35%).
FY 2026 revenue guidance raised to $108-114M (from $106-112M), midpoint implies 25% growth; expects continued Adj. EBITDA improvement.
Cash $25.6M, up 35% from Dec 2025; includes $16.8M ATM net proceeds, partially offset by Q1 cash outflows.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

BIODESIX INC reported the first quarter ended March 31, 2026 results: revenue $25.6 million, net income Net loss of $7.8 million. Guidance raised.

Period: the first quarter ended March 31, 2026
Revenue: $25.6 million
Net income: Net loss of $7.8 million
Guidance: raised
Result: reported results

Exact text from the filing

Biodesix Announces First Quarter 2026 Results and Highlights Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

BIODESIX INC filing history →

Source: SEC EDGAR

accession 0001193125-26-203936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.